Ayan, Gizem http://orcid.org/0000-0003-1889-9619
Esatoglu, Sinem Nihal http://orcid.org/0000-0001-5414-7305
Hatemi, Gulen http://orcid.org/0000-0002-1952-1135
Hamuryudan, Vedat http://orcid.org/0000-0001-6625-1652
Funding for this research was provided by:
Pfizer
Article History
Received: 24 February 2020
Accepted: 27 March 2020
First Online: 6 April 2020
Compliance with ethical standards
:
: This study was supported by an unrestricted grant from Pfizer. The authors, G. Ayan and S.N. Esatoglu declare no other competing interests. G. Hatemi has received research/grant support, consulting fees and speaker fees from Celgene, speaker fees from Abbvie, UCB pharma and Novartis.V. Hamuryudan has received honoraria and speaker fees from Amgen, MSD, Novartis, Pfizer, Roche UCB and Abbvie.
: This study was conducted in accordance with the Declaration of Helsinki. The ethics committee of Cerrahpasa Medical Faculty of Istanbul University-Cerrahpasa approved the study (89540/07.03.2018).
: Patients having a short-term (< 6 months) appointment gave their written consent at the time of their evaluation in the clinic (<i>n</i> = 52). We posted the consent to ten patients with appointments beyond 6 months after obtaining their verbal consent with a phone call. These patients signed and posted the consent forms back. Ten patients were either deceased or were receiving palliative care. Information on their outcome was obtained from central healthcare system database and from their family members after explaining the aim of the study. Verbal consent was obtained from family members to report their outcome information.
: Not applicable.
: Not applicable.
: Disease course and costs of a cohort of rheumatoid arthritis patients over a period of 6 years. Ann Rheum Dis, volume 78, supplement 2, year 2019, page A1577. ExternalRef removed.